Modeling sarcopenic obesity to advance healthy weight loss therapies
Background & aim: Incretin-based therapies have revolutionized obesity treatment by substantially reducing body weight and fat mass, yet are associated with a disproportionate loss of lean mass compared with traditional weight-loss interventions. Despite the great interest in the matter, primary…
Characterization of bimagrumab and apitegromab treatment in a mouse model of dexamethasone-induced muscle atrophy
Background & aim: Dexamethasone administration is a well-established avenue for modelling muscle atrophy. Variants of this approach have long been used to evaluate hypertrophic agents and have lately been involved in pre-clinical programs for muscle-targeted therapies. Here, we aimed to…
Orforglipron induces weight loss and activates appetite-suppressing brain regions in a humanized GLP-1R model
Background & aim: Orally administered small molecules GLP-1 receptor agonists such as orforglipron, represent a significant advancement for the treatment of obesity and type 2 diabetes, providing a valid alternative to peptide-based injectable therapies such as semaglutide. However, preclinical pharmacological…
Humanizing Dyslipidemia in MASH: A PCSK9-Driven dyslipidemia GAN DIO-MASH Model
Background & aim: Dyslipidemia, characterized by hyper-cholesterolemia and hypertriglyceridemia, is a central component of metabolic dysfunction-associated steatohepatitis (MASH) pathogenesis. While being highly instrumental in drug development, preclinical models of MASH often fail to recapitulate a human-like lipoprotein profile. To enhance…
Integrating AI-Based Fibrosis Staging and Pattern Analysis in a Translational Mouse Model of MASH
Background & aim: Histopathological fibrosis staging is a key endpoint in preclinical drug development for MASH. However, the MASH CRN (Kleiner) system assigns one global stage per biopsy, potentially obscuring subtle treatment-related collagen remodelling and tissue heterogeneity. We developed an…
Semaglutide reverses clinically relevant biomarker alterations in the biopsy-confirmed GAN DIO-MASH mouse model
Background & aim: The long-acting glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide was recently approved as the first GLP-1–based therapy for people with MASH and moderate-to-severe fibrosis. Clinical studies have demonstrated that semaglutide not only improves liver histology but also reverses…
Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease
Background & aim: Aims: Survodutide is a novel long-acting dual glucagon (GCGR)/glucagon-like peptide-1 (GLP-1R) receptor agonist currently in phase-3 clinical development for the treatment of people living with obesity and metabolic dysfunction-associated steatohepatitis. Emerging evidence suggests impaired renal GCGR function…
High-throughput 3D light-sheet imaging of mouse hindlimb enable skeletal muscle morphometrics in muscle wasting models
Background & aim: Conventional methods for assessing skeletal muscle remodelling, including lean mass, muscle weight, and histology, lack the spatial resolution and sensitivity to capture three-dimensional muscle architecture. Here, we developed a scalable, non-destructive, AI-enabled light-sheet fluorescence microscopy (LSFM) platform…